NaturVet unveils a bold rebrand at Global Pet Expo 2025
The pet supplement manufacturer showcases refreshed brand identity and latest innovations in pet health solutions for dogs and cats
ORLANDO, Fla., March 25, 2025 /PRNewswire-PRWeb/ -- NaturVet, a leader in pet health and wellness, will debut new product innovations and refreshed branding at Global Pet Expo from March 26-28 in Orlando, Florida. The brand's vet-formulated supplements will be on display at booth 4401, including the new All-In-One Daily Care soft chews for Puppy, Adult and Senior dogs and Lickable Supplements for dogs and cats.
"Global Pet Expo is the premier event to kick off the year in the pet industry, making it the perfect place to introduce our rebrand. We're thrilled to celebrate this milestone with everyone here in Orlando." said Geoff Granger, CEO at NaturVet.
NaturVet's new rebrand features updated packaging, a refreshed logo and enhanced brand messaging that highlights its pioneering devotion to pet health and wellness. The refreshed brand positioning is designed to resonate with pet parents while preserving the trust and proven effectiveness that have defined NaturVet for over 30 years.
In addition to the new branding, NaturVet is showcasing a variety of new, vet-formulated product lines at booth 4401, including:
All-In-One Puppy Daily Care: A soft chew supplement with a Hickory Smoked Bacon flavor designed to support the needs of growing puppies with six essential key benefits, including skeletal support, brain development, healthy digestion and immune health. Formulated for younger dogs, it features the exclusive dental care ingredient PlaqueOff® for added oral health support.
All-In-One Adult Daily Care: A 10-in-1 soft chew supplement designed to support adult dogs with targeted benefits, including joint health, digestion, immunity, skin and coat health and more. Featuring a delicious Hickory Smoked Bacon flavor and the exclusive dental care ingredient PlaqueOff®, it helps support overall health and well-being throughout adulthood.
All-In-One Senior Daily Care: An 8-in-1 soft chew supplement designed to support aging dogs by targeting areas such as joint health, mobility, gut health, while also providing brain, heart and vision support. It features the exclusive ingredient PlaqueOff® for dental care and tailored ingredients that help support longevity and immunity. With its Hickory Smoked Bacon flavor, the soft chew is easy to give to senior dogs.
Lickable Supplements for Cats: An irresistibly tasty, pump-dispensed Savory Salmon-flavored supplement designed for easy dosing. Available in Hip & Joint, Calming, and Multi-Vitamin formulas, it provides essential support in a mess-free format, making supplementation effortless for cat owners.
Lickable Supplements for Dogs: A delicious, Peanut Butter-flavored supplement for dogs, available in Hip & Joint, Calming and Multi-Vitamin formulas. Designed for easy dosing with a pump, it offers a convenient, mess-free alternative to traditional supplements while addressing key dog health and wellness needs.
Global Pet Expo visitors can visit the brand at booth #4401. To learn more about NaturVet and its entire line of products, please visit https://naturvet.com/.
Media Contact
Jessica Sepic, NaturVet, 916-285-9835, naturvet@merlotmarketing.com, https://naturvet.com/
View original content to download multimedia:https://www.prweb.com/releases/naturvet-unveils-a-bold-rebrand-at-global-pet-expo-2025-302410153.html
SOURCE NaturVet
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
New data from DR.CI:LABO™ at IMCAS Asia 2025 reinforces leadership in adjunctive clinical skincare for daily and post-IPL care for Asian skin
SINGAPORE, June 10, 2025 /PRNewswire/ -- Japan's clinic-born leading derma-cosmetics brand, unveiled new findings at IMCAS Asia 2025, reaffirming its position as the go-to skincare brand for Asian skin. The data demonstrated the efficacy of VC100 Essence Lotion EX and 377VC Radiance Serum in improving skin hydration, elasticity, and pigmentation when used daily and post-IPL[1] care. "At IMCAS Asia 2025, we're proud to present new clinical evidence that reflects the needs of today's consumers and supports their aesthetic and skincare choices. Our role is to provide safe, effective skincare solutions like VC100 Essence Lotion EX and 377VC Radiance Serum that can be used as daily skincare, enhance recovery and extend results of aesthetic treatments," said Dr. Sheila Chua, Board-Certified Dermatologist and Head of Medical & Safety Sciences, Skin Health & Beauty, Kenvue Asia Pacific. VC100 Essence Lotion EX: Now with clinically proven efficacy for regular daily and post-IPL care At IMCAS Asia 2025, presented new clinical data highlighting the benefits of twice-daily use of VC100 Essence Lotion EX over eight weeks on Asian skin. Powered by 100 trillion Micro-High Penetrating APPS Vitamin C, the formulation delivered visible improvements across key skin indicators including hydration, elasticity and gloss by 21.6%, 14.6%, 8.7% respectively, and reduction in hyperpigmentation by 5.9%.[2] The study also showed a significant boost in the synthesis of five different types of collagen, increased collagen density, and skin firmness. This builds on findings presented at the American Academy of Dermatology 2025, where twice daily use of VC100 Essence Lotion EX and Emulsion over a span of eight weeks showed a similar trend of improvement to IPL.[3],[4] When used in combination with IPL, hydration and elasticity improved by 25.4% and 15.5% respectively, compared to 20.8% and 10.9% with IPL alone, and hyperpigmentation reduction accelerated, with visible improvement by Week Two. 377VC Radiance Serum: A proven brightening adjunct for IPL-treated skin also shared clinical data on 377VC Radiance Serum at IMCAS. In a five-week, randomized controlled trial, participants who used the serum daily post-IPL showed a 31.88% reduction in Melasma Area and Severity Index and a 22.13% reduction in hyperpigmentation, compared to 8.92% and 8.52% in participants that only received IPL.[5] Skin image analysis further indicates reversing and reduced risk of potential re-darkening after IPL. The serum was well tolerated on treated skin in favorable state, supporting its use in post-IPL care and reaffirming its safety profile.[5] Findings presented at IMCAS from a survey of 844 dermatologists in China validated clinical approach and reinforces its clinical credibility: 83% agreed that 377VC Radiance Serum reduces melanin synthesis and improves skin brightness, Over 75% believed it enhances post-IPL outcomes and helps prevent post-inflammatory hyperpigmentation, and 99% acknowledged growing patient demand for adjunctive clinical skincare.[6] For a detailed overview of products and posters exhibited, refer to the Data and Product Fact Sheet. For more information, visit the website. About Since 1999, has pioneered the advancement of skincare solutions in collagen health. For over 25 years, is dedicated to providing skincare solutions that unlock the potential for beauty within every skin and democratize access to clinic level treatments for all. [1] Intense Pulsed Laser [2] Taichi Nishizawa et. al., "Ex-vivo and Clinical Study of an Amphiphilic Vitamin C Derivative to Enhance Dermal Collagen and Skin Gloss", IMACS Asia 2025, 6-8 June 2025, Bangkok, Thailand [3] Frequency of IPL treatment administered: 3 times every 2 weeks, over 8 weeks (IPL output: 10-13J, about 100 shots). [4] Masahiko Ando et. al., Clinical efficacy assessment of skin care formulations containing trisodium ascorbyl6-palmitate 2-phosphate (APPS) for pre-aging skin, Poster number 61671, American Academy of Dermatology Annual Meeting, 7-11 March 2025, Orlando, Florida [5] Yueying Fu et. al., "Clinical Safety and Efficacy of a Novel Topical Phenylethyl Resorcinol Formulation for Intense Pulsed Light Adjunctive Usage for Solar Lentigo and Melasma skin", IMACS Asia 2025, 6-8 June 2025, Bangkok, Thailand [6] Joleen Goh et. al., "Knowledge, Attitude, and Practice Towards the Adjunctive Perioperative Use of Phenylethyl Resorcinol with Aesthetic Treatments", IMACS Asia 2025, 6-8 June 2025, Bangkok, Thailand View original content to download multimedia: SOURCE Sign in to access your portfolio
Yahoo
4 hours ago
- Yahoo
APhA withholds endorsement of ACIP Adult Immunization Schedule
WASHINGTON, June 9, 2025 /PRNewswire/ -- APhA is the only pharmacy representative among several professional organizations that reviews and evaluates the ACIP Adult Immunization Schedule annually. Recently, there have been several updates to the COVID-19 vaccine recommendations made by the Department of Health & Human Services (HHS) and the Centers for Disease Control and Prevention (CDC). These changes include removing the recommendation for people who are pregnant to receive the COVID-19 vaccine. Studies have shown that people who are pregnant or were recently pregnant are: More likely to get very sick from COVID-19 compared to those who are not. More likely to need hospitalization, intensive care, or the use of a ventilator or special equipment to breathe if they do get sick from COVID-19. At increased risk of complications that can affect pregnancy and the baby, including preterm birth or stillbirth. COVID-19 vaccination during pregnancy has been proven safe and effective. Additionally, this vaccine is not associated with any fertility issues in either women or men. APhA's stance is that pregnancy is a high-risk condition; therefore, people who are pregnant should be recommended to receive the COVID-19 vaccine. The May 2025 updates to the COVID-19 vaccine recommendations do not appear to be based on the scientific evidence provided over the past few years. Considering this recent change, APhA has decided to withhold endorsing the current ACIP Adult Immunization Schedule issued on May 28, 2025. This decision was proposed by a group of APhA members who are immunization subject matter experts and approved by the APhA Board of Trustees. APhA requests, and is hopeful, that future updates of the Adult Immunization Schedule be based on scientific evidence and would reconsider its endorsement upon the schedule being discussed and recommended by ACIP. View original content to download multimedia: SOURCE American Pharmacists Association
Yahoo
5 hours ago
- Yahoo
Nigerian Medical Advocates Rally on Capitol Hill for J-1 Visa Fix and Immigrant Physician Bill
WASHINGTON, June 9, 2025 /PRNewswire/ -- The Nigerian Physician Advocacy Group (NPAG), will host a two-day Advocacy & Lobby Day on June 10–11, 2025, on Capitol Hill to highlight the vital role Nigerian American physicians play in filling healthcare shortages and call on Congress to remove systemic barriers to their continued service by reforming the J-1 visa program and passing the Conrad State 30 and Physician Access Reauthorization Act (H.R. 1201), also known as the "Doctors in Our Borders" bill. The NPAG delegation will be led by Dr. Susan Edionwe, Nigerian American physicians, health advocates, and community leaders. This initiative comes amid targets on international students at U.S. universities and growing concerns over the increasing number of J-1 visa denials, which prevent qualified international medical graduates (IMGs)—especially Nigerian-trained physicians—from contributing their expertise to underserved and rural communities across the United States. Nigerian American physicians have played an important role in filling healthcare shortages in the United States and the advancement of our country's healthcare system is dependent on the removal of systemic barriers to their continued service. "Doctors from Nigeria and across Africa have long served in America's most vulnerable communities—from inner cities to remote rural counties," said Dr. Susan Edionwe. "Fixing the J-1 process and passing H.R. 1201 is essential to ensuring our communities have access to the care they desperately need." "NPAG encourages policymakers, allies, and the media to recognize the indispensable contribution of Nigerian and African-trained doctors to the American healthcare system—and to take legislative action to protect and expand their role in advancing national health equity," said Dr. Susan Edionwe. About Conrad State 30 and Physician Access Reauthorization Act (H.R. 1201): H.R. 1201 a bipartisan bill, would reauthorize and expand the Conrad 30 waiver program, which allows J-1 physicians to remain in the U.S. after residency by serving in Health Professional Shortage Areas (HPSAs). The legislation provides states with greater flexibility, increases waiver caps, and reduces processing delays—ensuring medically underserved communities continue receiving essential care. About NPAG: The Nigerian Physician Advocacy Group is a national coalition of Nigerian American doctors and advocates committed to advancing health equity, shaping inclusive immigration policy, and addressing physician workforce challenges in the United States. View original content to download multimedia: SOURCE Nigerian Physician Advocacy Group (NPAG)
